编者按:近期,由北京白求恩公益基金会发起,多位内分泌领域核心专家牵头撰写完成的《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。这是中国首个专门针对SGLT2i联合二甲双胍治疗T2DM临床应用的指导性文件,为临床医生了解并规范地应用...
编者按:近期,由北京白求恩公益基金会发起,多位内分泌领域核心专家牵头撰写完成的《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。这是中国首个专门针对SGLT...
编者按:近期,由北京白求恩公益基金会发起,多位内分泌领域核心专家牵头撰写完成的《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。这是中国首个专门针对SGLT2i联合二甲双胍治疗T2DM临床应用的指导性文件,为临床医生了解并规...
SGLT2 inhibitorBackground: Hyperglycemia is the most common side-effect of phosphatidylinositol 3-kinase (PI3K) inhibitors that are approved for the treatment of some advanced or metastatic breast cancers. This side-effect is likely due to the central role of PI3K in insulin signalling. Here we ...
16. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis o...
SGLT2 inhibitors improve hyperglycemia with a decline in body weight and blood pressure, the outcomes touted to be of major importance in management of type 2 diabetes. However, the efficacy in lowering glycemia is very modest and imparts an undue cost burden on patients. Moreover, the ...
The domestic diabetes treatment market will likely undergo fierce competition as new SGLT-2 inhibitors, including the generic products of patent-expired Forxiga (dapagliflozin), new drug enavogliflozin, and other combo drugs will hit the market next month. ...
ableHFwhohadbeentakingatleastoneantidiabeticdrugsother thanSGLT2inhibitorsformorethan1yearbetweenDecember2015 andMarch2016attheparticipatingcenters.Allpatientshada previoushistoryofHF,buttheywereinclinicallystablecondit ionatthetimeofenrollment,definedasanexacerbationofHFs ...
Takeaway In patients with type 2 diabetes (T2D), sodium-glucose co-transporter-2 inhibitors (SGLT2i) significantly reduced the risk of all-cause mortality and hospitalisations for heart failure (HF) and chronic kidney disease (CKD) compared with dipeptidyl peptidase-4 inhibitors (DPP4i), irrespe...
Several agents with similar profiles are racing to market, reminiscent of the sprint undertaken by the dipeptidyl peptidase-4 inhibitors. These drugs appear to have similar benefits and risk within the class, which include meaningful reductions on HbA1c and FPG and an increase in the risk for ...